Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 21;74(5):2452–2466. doi: 10.1002/hep.31995

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

FIG. 5 — Serum TSP‐2 levels identified advanced fibrosis patients among patients with NAFLD. (A) Relative serum TSP‐2 levels based on fibrosis staging in 213 patients with biopsy‐proven NAFLD (*P < 0.01). (B) Receiver operating characteristic curve of the performance of serum TSP‐2 levels, FIB‐4 index, HA, and NFS in the diagnosis of advanced liver fibrosis (F3‐F4) among patients with NAFLD. The AUROC is shown. (C‐E) Correlation of serum TSP‐2 levels with serum AST levels (C), serum HA levels (D), and NFS (E). (F,G) Kaplan‐Meier curves of the cumulative incidence rate of liver cancer (F) in 164 patients with NAFLD and decompensated cirrhotic events, including esophageal varices, ascites, and hepatic encephalopathy (G) in 163 patients with NAFLD stratified by serum TSP‐2 levels. Number of patients at risk is shown at each observation period.